Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × HR+ Breast Cancer × sintilimab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 3 Stomach Neoplasms 1 Nasopharyngeal Carcinoma 1 Locally Advanced Cervical Carcinoma 1 Liver Neoplasms 1 Liver Diseases 1 HR+ Breast Cancer 1 Advanced Colorectal Carcinoma 1

Interventions

sintilimab 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06734533 2024-12-16

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Hunan Cancer Hospital

HR+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡